SEC EDGARAUG 211 min read$RGEN

Loeillot Olivier sold $977K of RGEN

Loeillot Olivier (Chief Executive Officer) sold 5,426 shares of REPLIGEN CORP (RGEN) at $180.00 ($0.98M total) on 2026-08-20 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Loeillot Olivier

Published Aug 21, 2026, 8:06 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Aug 21, 2026, 8:36 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

alphai market briefInsider activity

Primary signal

$RGEN

Neutral

medium confidence

Mentioned

$RGEN

Relevance

4/10

alphai data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$RGENNeutralLow

Why it matters

The disclosed sale is modest and unlikely to move the stock significantly.

Market read

A routine insider sale with limited trading relevance.

What to watch

Potential upcoming corporate actions or personal tax planning not disclosed.

Relevance 4/10Novelty 5/10Timing: today

Background

Form 4 filings disclose insider transactions; investors monitor them for signals.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$RGENNeutralMedium confidence

Context

CEO Olivier Loeillot sold 5,426 shares for $976,680 via a 10b5‑1 plan, reducing his stake to 54,246 shares.

Expected impact

Potential minor downward pressure, likely within normal volatility range.

Evidence & confidence

The sale amount is under $1M and represents a small percentage of total holdings, limiting market impact.

Market effects

Sector

Minimal effect on biotech/healthcare sector; insider sales are routine.

Regional

No regional impact beyond investor perception of RGEN.

Global

Limited global relevance; only relevant to RGEN shareholders.

Counterpoint

What could challenge this read

The sale could be a routine liquidity event, not a bearish signal.

Key entities

Person
Loeillot Olivier
Chief Executive Officer of Repligen Corp.
Company
Repligen Corp
Biopharmaceutical company listed on NASDAQ under ticker RGEN.

Read at source ← All news

AUG 27

$RGENHighAI 8/10

Why Is Repligen (RGEN) Up 27.7% Since Last Earnings Report?

Repligen (RGEN) shares rose 27.7% since its last earnings report, beating Q2 estimates with $0.54 EPS and $204.1M revenue. The company raised 2026 guidance, expecting $813M-$835M revenue and $2.03-$2.09 EPS. Analysts have upwardly revised estimates, giving RGEN a Zacks Rank #1 (Strong Buy).

finance.yahoo.com2 min

AUG 25

$MRKHighAI 8/10

Cancer Vaccine Breakthrough Lifts 5 Biotech Names. Here’s Who’s Best Positioned.

MRK and MRNA's intismeran autogene showed positive Phase 3 results in melanoma, beating Keytruda alone on recurrence-free survival. BNTX rose 21.6%, ILMN 15.6%, PACB 5.8%, RGEN and DHR also mentioned. Analysts project varying revenue forecasts for the therapy. Keytruda's U.S. patent cliff is in 2028, with 2025 sales at $31.641B.

yahoo.com3 min

AUG 20

$RGENHighAI 8/10

Repligen rises as investors continue to digest raised 2026 guidance and the BioLife deal

Repligen (RGEN) shares rose 3.5% following strong Q2 2026 results, raised 2026 guidance, and the planned BioLife Solutions acquisition. Revenue was $204M with double-digit YoY growth. Full-year 2026 organic revenue growth guidance increased to 10.5%-13.5%, and adjusted EPS outlook raised to $2.03-$2.09. The BioLife deal, valued at $1.5B, is expected to expand Repligen's cell therapy tools.

quiverquant.com2 min

AUG 19

$TEMHighAI 8/10

TEM, BNTX, MRVI, RGEN, NVAX Stock Rallies As Moderna-Merck Cancer Vaccine Clears Late-stage Trial

Shares of BioNTech (BNTX), Moderna (MRVI), Regeneron (RGEN), and Novavax (NVAX) rose 20%, 25%, 6%, and 6% respectively after a Moderna-Merck cancer vaccine trial succeeded. Analysts expect benefits for Merck and suppliers like Repligen, Danaher, Thermo Fisher, and Maravai. TEM stock gained 2% YTD, with 8/16 analysts rating it 'Buy' or higher, and a 27% potential upside from its last close.

finance.yahoo.com2 min

AUG 6

$BLFSMed

BioLife Solutions (NASDAQ: BLFS) plans cash-stock merger with Repligen

BioLife Solutions (NASDAQ: BLFS) said it plans a cash-stock merger with Repligen, according to the company. The deal terms and timing were not provided in the excerpt, but it would combine the businesses under a merger agreement.

stocktitan.net2 min

JUL 30

$RGENHighAI 9/10

Repligen Q2 Earnings Call Highlights

Repligen (NASDAQ:RGEN) reported Q2 growth in chromatography revenue in the low double digits, driven by OPUS columns and demand from CDMOs and biopharma. Filtration revenue rose slightly, with headwinds tied to gene therapy issues, ATF customer inventory, site readiness delays, and the Polymem divestiture. Repligen raised 2026 revenue outlook to $813M-$834M and EPS to $2.03-$2.09, excluding BioLife acquisition.

yahoo.com7 min